SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gordon James who wrote (307)9/6/1999 8:55:00 PM
From: Vector1  Read Replies (1) of 666
 
Gordon,
I am not particularly concerned with the CLTR label although the stock would be hurt if it is only approved for transformed Ig NHL. CLTR's multi-center phase III in refactory patients showed clear efficacy and longer duration than chemo. Rit has never been attempted clinically against such a refactory patient population. I think the typical patient had failed chemo at least four times and had a median progression to disease of 3 months.
The most powerful argument against CLTR IMO is that Rit plus CHOP is the gold standard and Bex will only be used for salvage patients. Even if this is the case the salvage population is enough to bring a satisfactory return from current levels if Bex is approved. The home run is off label use of Bex in first line treatment.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News